Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myxothiazol is a natural antifungal antibiotic produced by the myxobacterium *Myxococcus fulvus*. It acts as a potent inhibitor of the mitochondrial electron transport chain complex III (cytochrome bc1 complex), specifically binding to the quinol oxidation (Qo) site. This competitive inhibition blocks electron transfer to the Rieske iron-sulfur protein and disrupts cellular respiration in fungi and some Gram-positive bacteria. Myxothiazol is primarily used as a research tool for studying mitochondrial function and bioenergetics rather than as a therapeutic drug[5][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on myxothiazol.